The importance of non-motor symptoms in the clinical picture of motor neuron disease

Non-motor symptoms are an obligate sign of motor neuron disease and can often serve as a rather sensitive indicator of the general functional state of ALS patients. Gastrointestinal disorders, weight loss, pain, sweating and anxiety prevail in the structure of non-motor symptoms in ALS patients The presence of non-motor symptoms in patients indicates the multisystemic […]

Authors: V. V. KOSTENKO, Y. I. GOLOVCHENKOP. L. Shupyk National Medical Academy оf Postgraduate Education Kyiv

Posted: Ukrainian Neurological Journal 2020, №3

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Abstract. Edaravone isa low-molecular-weight antioxidant drug targeting peroxyl radicals among many types of reactive oxygen species. Because of its amphiphilicity, it scavenges both lipid- and water-soluble peroxyl radicals by donating an electron to the radical. Thus, it inhibits the oxidation of lipids by scavenging chain-initiating water-soluble peroxyl radicals and chain-carrying lipid peroxyl radicals. In 2001, it […]

Authors: Kazutoshi Watanabe, Masahiko Tanaka, Satoshi Yuki, Manabu Hirai, Yorihiro Yamamoto

Posted: J. Clin. Biochem. Nutr. January 2018. Vol. 62, № 1. Р. 20-38

Ukrainian legislation on the prevention and treatment of rare (orphan) diseases

From 01 January 2015, amendments to the Fundamentals of Legislation of Ukraine on Health Care implemented by the Law of Ukraine No. 1213-VII dated 15 April 2014, have become effective. According to the implemented amendments to the legislation, patients with rare (orphan) diseases shall be provided, on a continuous and free basis, with medicinal products for the […]

Authors: Верховна Рада України; Кабінет міністрів України.

Posted: Відомості Верховної Ради (ВВР), 2014, № 26; Постанова Кабінету міністрів України №160 від 31.03.2015 р.

Extended revised ALS Scale (ALSFRS-R)

Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) is a tool for monitoring the progression of disability in patients with amyotrophic lateral sclerosis (ALS). The disadvantage of ALSFRS is that its rating of the bulbar functions and limb functionality is overweighted compared to the rating of respiratory dysfunction. A revised ALS functional rating scale (ALSFRS-R) retains the properties […]

Authors: ALS Functional Rating Scale Revised (ALS-FRS-R).

Posted: version of May 2015.

Safety and efficacy of edarowon in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study

This randomized double-blind parallel trial (Phase III) was attended by patients aged 20-75 years with grade 1 or 2 ALS from 31 hospitals in Japan. Patients had a score of at least 2 for each of all 12 points of ALSFRS-R, a forced vital lung capacity of ≥ 80% and an established or suspected ALS […]

Authors: The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group.

Posted: сайт, 15 травня 2017.

In 2017, the FDA approved a new drug for the treatment of lateral amyotrophic sclerosis (press release, in English)

On 05 May 2017, US Food and Drug Administration (FDA) approved edaravone as an officially recommended drug product for the treatment of patients with amyotrophic lateral sclerosis (ALS). The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. “After learning […]

Authors: The U.S. Food and Drug Administration.

Posted: офіційний сайт FDA, травень 2017.